Annovis Bio (ANVS) Earnings Date, Estimates & Call Transcripts $2.60 -0.09 (-3.38%) Closing price 08/19/2025 03:58 PM EasternExtended Trading$2.65 +0.05 (+1.92%) As of 08/19/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Annovis Bio Earnings Summary Annovis Bio released Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.32, which beat the consensus estimate of -$0.36 by $0.04. With a trailing EPS of -$2.04, Annovis Bio's earnings are expected to grow next year, from ($2.19) to ($1.68) per share. Latest Q2 Earnings DateAug. 12EstimatedConsensus EPS (Aug. 12) -$0.36 Actual EPS (Aug. 12) -$0.32 Beat By $0.04 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Annovis Bio Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataANVS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Annovis Bio Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.47-$0.47-$0.47Q2 20251-$0.36-$0.36-$0.36Q3 20251-$0.38-$0.38-$0.38Q4 20251-$0.45-$0.45-$0.45 FY 2025 4 -$1.66 -$1.66 -$1.66 Q1 20261-$0.42-$0.42-$0.42Q2 20261-$0.39-$0.39-$0.39Q3 20261-$0.43-$0.43-$0.43Q4 20261-$0.42-$0.42-$0.42 Annovis Bio Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025-$0.36-$0.32+$0.04-$0.32--5/13/2025Q1 2025-$0.47-$0.32+$0.15-$0.32--3/21/2025Q4 2024-$0.38-$0.43 -$0.05-$0.43--11/8/2024--$0.64-$0.97 -$0.33-$0.97--8/15/2024Q2 2024-$0.63-$0.44+$0.19-$0.44--5/13/2024Q1 2024-$0.87-$0.72+$0.15-$0.72--3/29/2024Q4 2023--$1.09-$0.15--11/8/2023Q3 2023-$1.10-$1.63 -$0.53-$1.63-- Annovis Bio Earnings - Frequently Asked Questions When did Annovis Bio announce their last quarterly earnings? Annovis Bio (NYSE:ANVS) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on ANVS's earnings history. Did Annovis Bio beat their earnings estimates last quarter? In the previous quarter, Annovis Bio (NYSE:ANVS) reported ($0.32) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.36) by $0.04. Learn more on analysts' earnings estimate vs. ANVS's actual earnings. How much profit does Annovis Bio generate each year? Annovis Bio (NYSE:ANVS) has a recorded net income of -$24.59 million. ANVS has generated -$2.04 earnings per share over the last four quarters. What is Annovis Bio's EPS forecast for next year? Annovis Bio's earnings are expected to grow from ($2.19) per share to ($1.68) per share in the next year. More Earnings Resources from MarketBeat Related Companies ALX Oncology Earnings Results Entrada Therapeutics Earnings Results Organigram Global Earnings Results CytomX Therapeutics Earnings Results Eupraxia Pharmaceuticals Earnings Results enGene Earnings Results Puma Biotechnology Earnings Results Editas Medicine Earnings Results Instil Bio Earnings Results C4 Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? This page (NYSE:ANVS) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access